The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...

Topic engagement Tell us about the 5 key areas for quality improvement which you consider as having the greatest potential to improve the quality of care in this area. Closing date for comments: ...

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

The FDG has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FDG has been sent to ...

01 July 2025 via Zoom Draft Agenda The meeting will take place as a meeting via Zoom, a secure web conferencing tool. This meeting will run from 9:00am to 5:00pm, although timings may be subject to ...

Our updated guideline reflects this change in practice and in doing so they recommend an earlier use of the SGLT2 inhibitors empagliflozin and dapagliflozinthan we’ve recommended before. It means they ...

NICE is unable to make a recommendation on fosdenopterin (Nulibry) for treating molybdenum cofactor deficiency type A in people of all ages. This is because Sentynl Therapeutics has withdrawn from the ...

Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults. Last reviewed: 18 June 2025 Next review: This guidance will be reviewed if there is ...

This means the medicines should not be provided on the NHS as they are not good value for money. Last month the appraisal committee met to consider new information submitted as part of its additional ...

Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults. Last reviewed: 25 June 2025 Next review: This guidance will be reviewed if ...

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone. The guidance recommends the ...